SLC1A5 and cancer: A recent study identified a small-molecule drug candidate, IMD-0354, that targets the glutamine transporter SLC1A5 to inhibit the uptake of glutamine by cancer cells, blocking an important energy source for cancer cells and thus, slowing their growth (132).